Related Experiment Video

Updated: Jun 19, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Pediatric multiple sclerosis

E Ann Yeh1, Tanuja Chitnis, Lauren Krupp

  • 1Pediatric Multiple Sclerosis Center of the Jacobs Neurological Institute, University at Buffalo, The State University of New York, Buffalo, NY, USA. ayeh@thejni.org

Nature Reviews. Neurology
|October 15, 2009
PubMed

Insights

Pediatric multiple sclerosis (MS) is rare, affecting up to 5% of cases. Recent research offers new insights into its causes, treatment, and differences in immune responses compared to adult MS.

Area of Science:

  • Neurology
  • Immunology
  • Pediatrics

Background:

  • Pediatric multiple sclerosis (MS) constitutes up to 5% of all MS diagnoses.
  • Recent research has significantly advanced understanding of its treatment, pathogenesis, demographics, and natural history.
  • Genetic and environmental factors play crucial roles in the development of pediatric MS.

Purpose of the Study:

  • To provide a comprehensive review of current knowledge on pediatric MS.
  • To highlight recent advances in the understanding and management of pediatric MS.
  • To discuss differences in immune responses and CNS environments between pediatric and adult MS patients.

Main Methods:

  • Review of recent scientific literature (past 5 years) on pediatric MS.
  • Analysis of clinical, MRI, and laboratory data from prepubertal and postpubertal children.
  • Evaluation of safety and efficacy of adult MS therapies in pediatric populations.

Main Results:

  • Evidence suggests distinct immune responses and central nervous system (CNS) environments in younger children with MS compared to older children and adults.
  • Therapies used for adult MS appear to be safe when applied to pediatric MS patients.
  • While randomized controlled trials are lacking, existing data support the use of adapted adult therapies.

Conclusions:

  • Pediatric MS exhibits unique characteristics necessitating tailored research and understanding.
  • Current therapeutic approaches, adapted from adult MS, show promise and appear safe for pediatric use.
  • Further research, including dedicated clinical trials, is warranted to optimize pediatric MS management.

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy07:20

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy

Published on: August 9, 2024

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...